Table 3 Medication exposure during first 12 months and at 12 months by JIA category
Any | NSAIDS | Oral steroids | IV steroids | Methotrexate | bDMARD | Ocular steroids | Steroid joint injections | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ever n (%) | Ever n (%) | At 12 m n (%) | Ever n (%) | At 12 m n (%) | Number given IV steroids n(%) | Ever n (%) | Med. time to (m) | At 12 m n (%) | Ever n (%) | Med. time to (m) | At 12 m n (%) | Ever n (%) | At 12 m n (%) | Ever n (%) | Med joint injections per patienta (range) | |
Oligoarticular | 43(90) | 43 (90) | 13 (27) | 7 (15) | 4 (8) | 0 (0) | 9 (19) | 2.1 | 9 (19) | 1 (2) | 12.2 | 1 (2) | 8(17) | 4(8) | 45 (94) | 1 (0–3) |
Polyarticular RF - | 34 (100) | 33 (97) | 17 (50) | 21 (62) | 5 (15) | 2 (6) | 32 (94) | 0.8 | 32 (94) | 6 (18) | 5.4 | 6 (18) | 0 (0) | 0 (0) | 16 (47) | 0 (0–4) |
Undifferentiated | 17 (100) | 17 (100) | 12 (71) | 13 (76) | 5 (29) | 1 (6) | 13 (76) | 0 | 12 (71) | 3 (18) | 5.5 | 3 (18) | 0 (0) | 0 (0) | 10 (59) | 1 (0–2) |
Enthesitis related arthritis | 13 (100) | 13 (100) | 7 (54) | 10 (76) | 4 (31) | 0 (0) | 12 (92) | 3.1 | 8 (62) | 4 (31) | 5.8 | 4 (31) | 0 (0) | 0 (0) | 5 (38) | 0 (0–3) |
Systemic | 10 (100) | 9 (90) | 5 (50) | 10 (100) | 3 (30) | 6 (60) | 7 (70) | 0.5 | 6 (60) | 3 (30) | 2.4 | 2 (20) | 0 (0) | 0 (0) | 2 (20) | 0 (0–1) |
Psoriatic arthritis | 9 (100) | 8 (89) | 5 (56) | 7 (78) | 2 (22) | 0 (0) | 7 (78) | 1.1 | 7 (78) | 2 (22) | 6.0 | 2 (22) | 1 (11) | 1 (11) | 5 (56) | 1 (0–1) |
Polyarticular RF + | 3 (100) | 3 (100) | 1 (33) | 3 (100) | 0 (0) | 1 (33) | 3 (100) | 0 | 3 (100) | 1 (33) | 4.7 | 1 (33) | 0 (0) | 0 (0) | 0 (0) | 0 (0–0) |
Overall | 129 (96) | 126 (94) | 60 (45) | 71 (53) | 23 (17) | 10 (7) | 83 (62) | 0.9 | 77 (57) | 20 (15) | 5.5 | 19 (14) | 9 (7) | 5 (4) | 83 (62) | 0 (0–4) |